Gossamer Bio, Inc. $GOSS Shares Sold by Siren L.L.C.

Key Points

• Siren L.L.C. reduced its stake in Gossamer Bio by 3.8%, now holding about 5.2 million shares valued at approximately $5.73 million.
• Gossamer Bio's stock has seen a 12.3% increase recently, trading at $3.11 with a market capitalization of $707.15 million.
• Analysts have mixed views on Gossamer Bio, with a consensus target price of $8.50 and varying ratings from "buy" to "sell" across different brokerages.

Siren L.L.C. cut its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 3.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,208,968 shares of the company's stock after selling 207,000 shares during the period. Siren L.L.C. owned approximately 2.29% of Gossamer Bio worth $5,730,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GOSS. Graham Capital Management L.P. acquired a new stake in shares of Gossamer Bio during the fourth quarter valued at about $32,000. Virtu Financial LLC acquired a new position in shares of Gossamer Bio in the first quarter valued at approximately $38,000. Invesco Ltd. acquired a new position in shares of Gossamer Bio in the first quarter valued at approximately $48,000. Velan Capital Investment Management LP acquired a new position in shares of Gossamer Bio in the fourth quarter valued at approximately $68,000. Finally, Bank of America Corp DE grew its holdings in shares of Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock valued at $77,000 after purchasing an additional 43,866 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Trading Up 12.3%

NASDAQ GOSS opened at $3.11 on Thursday. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of 6.70. Gossamer Bio, Inc. has a 52 week low of $0.66 and a 52 week high of $3.40. The stock has a market capitalization of $707.15 million, a PE ratio of -5.02 and a beta of 1.95. The firm has a 50 day moving average of $1.99 and a two-hundred day moving average of $1.43.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The company had revenue of $11.49 million during the quarter, compared to analysts' expectations of $4.12 million. As a group, research analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on GOSS. Scotiabank began coverage on shares of Gossamer Bio in a report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price objective for the company. Wedbush lifted their price objective on shares of Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, August 6th. The Goldman Sachs Group lifted their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, May 16th. Finally, Wall Street Zen cut shares of Gossamer Bio from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Gossamer Bio has an average rating of "Buy" and a consensus target price of $8.50.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.